MCID: FTT001
MIFTS: 62

Fatty Liver Disease

Categories: Gastrointestinal diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease 12 40 14
Fatty Liver 72 51 41 69
Fatty Liver, Alcoholic 41 69
Alcoholic Fatty Liver 12
Fatty Change of Liver 12
Fatty Liver Alcoholic 51
Steatosis of Liver 12
Hepatic Lipidosis 12
Steatohepatitis 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9452
ICD10 32 K70.0
ICD9CM 34 571.0

Summaries for Fatty Liver Disease

MedlinePlus : 40 What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who gets fatty liver disease? Researchers do not know the cause of nonalcoholic fatty liver (NAFLD). They do know that it is more common in people who Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25 percent of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How do I know if I have fatty liver disease? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary : Fatty Liver Disease, also known as fatty liver, is related to nonalcoholic steatohepatitis and liver disease. An important gene associated with Fatty Liver Disease is ADIPOQ (Adiponectin, C1Q And Collagen Domain Containing), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Rosiglitazone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and skin, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology : 12 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia : 72 Fatty liver is a reversible condition wherein large vacuoles of triglyceride fat accumulate in liver... more...

Related Diseases for Fatty Liver Disease

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 nonalcoholic steatohepatitis 32.6 ADIPOQ IL6 INS KRT18 LEP PNPLA3
2 liver disease 31.5 ADIPOQ ADIPOR2 CYP2E1 GGT1 IL6 INS
3 hepatitis 31.3 GGT1 MAPK8 SLC17A5 TNF
4 arteries, anomalies of 30.6 ADIPOQ IL6 INS LEP TNF
5 coronary artery anomaly 30.6 ADIPOQ IL6 INS RETN
6 morbid obesity 30.5 ADIPOQ INS LEP LEPR RETN
7 apnea, obstructive sleep 30.4 ADIPOQ IL6 INS LEP TNF
8 viral hepatitis 30.4 GGT1 KRT18 SLC17A5 TNF
9 pancreas disease 30.3 IL6 INS LEP TNF
10 diabetes mellitus 30.3 ADIPOQ IL6 INS INSR LEP MAPK8
11 sleep apnea 30.3 ADIPOQ IL6 INS LEP LEPR TNF
12 coronary heart disease 1 30.3 ADIPOQ INS MTTP
13 hypertension, essential 30.1 ADIPOQ INS INSR LEP RETN
14 alcoholic liver cirrhosis 30.1 CYP2E1 PNPLA3 SLC17A5 TNF
15 liver cirrhosis 30.1 ADIPOQ CYP2E1 GGT1 KRT18 SLC17A5
16 cholangitis 30.0 GGT1 IL6 TNF
17 hyperglycemia 29.9 ADIPOQ INS INSR LEP
18 heart disease 29.9 ADIPOQ IL6 INS PPARA TNF
19 glucose intolerance 29.9 ADIPOQ INS INSR LEP LEPR RETN
20 insulin-like growth factor i 29.6 INS INSR LEP
21 body mass index quantitative trait locus 11 28.9 ADIPOQ ADIPOR2 CYP2E1 GGT1 IL6 INS
22 fatty liver disease, nonalcoholic 1 12.6
23 fatty liver disease, nonalcoholic 2 12.2
24 visceral steatosis 11.1
25 visceral steatosis, congenital 11.1
26 morbid obesity and spermatogenic failure 10.8
27 body mass index quantitative trait locus 9 10.7
28 body mass index quantitative trait locus 8 10.7
29 body mass index quantitative trait locus 7 10.7
30 body mass index quantitative trait locus 12 10.7
31 body mass index quantitative trait locus 14 10.7
32 body mass index quantitative trait locus 18 10.7
33 body mass index quantitative trait locus 4 10.7
34 body mass index quantitative trait locus 10 10.7
35 scorpion envenomation 10.6 IL6 TNF
36 nontuberculous mycobacterial lung disease 10.6 ADIPOQ LEP TNF
37 idiopathic edema 10.6 ADIPOQ INS PPARA
38 endocrine pancreas disease 10.6 ADIPOQ INS LEP
39 3-hydroxyacyl-coa dehydrogenase deficiency 10.6 ADIPOQ INS PPARA
40 acquired generalized lipodystrophy 10.5 ADIPOQ LEP RETN
41 idiopathic recurrent pericarditis 10.5 ADIPOQ LEP RETN
42 fibrosis of extraocular muscles, congenital, 1 10.5
43 hemorrhagic fever 10.5 IL6 SLC17A5 TNF
44 coronary artery aneurysm 10.5 ADIPOQ LEP RETN
45 endometritis 10.5 IL6 SLC17A5 TNF
46 insulin autoimmune syndrome 10.5 INS INSR
47 leukomalacia 10.5 IL6 SLC17A5 TNF
48 protein-energy malnutrition 10.5 IL6 LEP TNF
49 severe pre-eclampsia 10.5 ADIPOQ LEP LEPR
50 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL6 TNF

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):


Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:



Diseases related to Fatty Liver Disease

Symptoms & Phenotypes for Fatty Liver Disease

MGI Mouse Phenotypes related to Fatty Liver Disease:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 LEP CYP2E1 INS FABP1 GGT1 ADIPOQ
2 growth/size/body region MP:0005378 10.34 ADIPOR2 KRT18 INS LEP GGT1 ADIPOQ
3 adipose tissue MP:0005375 10.33 LEP INS ADIPOQ INSR LEPR IL6
4 liver/biliary system MP:0005370 10.33 LEP CYP2E1 INS FABP1 ADIPOQ INSR
5 behavior/neurological MP:0005386 10.31 IL6 ADIPOR2 INS CYP2E1 LEP GGT1
6 mortality/aging MP:0010768 10.27 KRT18 INS LEP CYP2E1 GGT1 ADIPOQ
7 cardiovascular system MP:0005385 10.26 IL6 INS CYP2E1 LEP ADIPOQ INSR
8 endocrine/exocrine gland MP:0005379 10.21 IL6 ADIPOR2 INS LEP GGT1 ADIPOQ
9 immune system MP:0005387 10.2 LEPR IL6 INS LEP GGT1 ADIPOQ
10 integument MP:0010771 10.09 IL6 INS LEP GGT1 ADIPOQ LEPR
11 muscle MP:0005369 9.97 INS LEP ADIPOQ INSR LEPR IL6
12 neoplasm MP:0002006 9.8 IL6 CYP2E1 LEP ADIPOQ LEPR MAPK8
13 renal/urinary system MP:0005367 9.76 IL6 INS LEP GGT1 ADIPOQ INSR
14 reproductive system MP:0005389 9.61 LEPR ADIPOR2 IL6 INS LEP GGT1
15 vision/eye MP:0005391 9.23 LEPR IL6 INS LEP GGT1 SLC17A5

Drugs & Therapeutics for Fatty Liver Disease

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 424)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 4,Phase 2 122320-73-4 77999
2
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
3
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051 23994
6
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
7
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 4091 14219
8
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
9
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
10
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
11
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
12
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
13
Amlodipine Approved Phase 4 88150-42-9 2162
14
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
15
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
16
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
17
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
18
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
19
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
20
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
21
Rifampin Approved Phase 4,Phase 1 13292-46-1 5381226 5458213
22
Tamoxifen Approved Phase 4 10540-29-1 2733526
23
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
24
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
25
Gliclazide Approved Phase 4 21187-98-4 3475
26
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 657311 5754
27
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
28
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
29
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
30
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
31
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
32
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
33
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
34
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
35
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
36
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3 80621-81-4 6436173
37
Insulin Aspart Approved Phase 4 116094-23-6 16132418
38
Insulin Detemir Approved Phase 4 169148-63-4 5311023
39 Racepinephrine Approved Phase 4,Phase 2 329-65-7
40
Glimepiride Approved Phase 4 93479-97-1 3476
41
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
42
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
43
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
44
Saxagliptin Approved Phase 4 361442-04-8 11243969
45
Choline Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 62-49-7 305
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
47 Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
48
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-02-9 14985
50
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 65-23-6 1054

Interventional clinical trials:

(show top 50) (show all 857)

# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
6 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
7 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
8 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
9 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
10 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
11 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
12 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
13 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
14 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
15 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
16 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
17 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
18 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
19 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
20 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
21 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
22 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
23 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
24 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
25 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
26 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
27 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
28 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
29 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
30 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
31 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
32 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
33 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
34 Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
35 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
36 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
37 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4 Metformin;Placebo
38 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
39 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
40 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
41 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
42 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4 Liraglutide;Saline
43 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
44 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
45 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4 Exenatide;insulin glargine
46 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Recruiting NCT02051842 Phase 4 Metadoxine
47 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
48 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
49 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Recruiting NCT02637973 Phase 4 Empagliflozin;Placebo
50 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Genetic Tests for Fatty Liver Disease

Anatomical Context for Fatty Liver Disease

MalaCards organs/tissues related to Fatty Liver Disease:

38
Liver, Testes, Skin, Eye, Endothelial, Kidney, Ovary

Publications for Fatty Liver Disease

Articles related to Fatty Liver Disease:

(show top 50) (show all 1443)
# Title Authors Year
1
Evaluation of nonalcoholic fatty liver disease using magnetic resonance in obese children and adolescents. ( 29438686 )
2018
2
Statin Use In Cirrhosis from Fatty Liver Disease. ( 29443384 )
2018
3
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough. ( 29427494 )
2018
4
Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. ( 29428103 )
2018
5
Changes in inflammatory factors and prognosis of patients complicated with non-alcoholic fatty liver disease undergoing coronary artery bypass grafting. ( 29434690 )
2018
6
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
7
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. ( 29438460 )
2018
8
Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. ( 29451179 )
2018
9
PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. ( 29452087 )
2018
10
Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. ( 29434074 )
2018
11
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. ( 29449533 )
2018
12
<i>Helicobacter pylori</i> Infection Is Not Associated with Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study in China. ( 29445363 )
2018
13
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
14
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
15
Relationship between diverticulosis and nonalcoholic fatty liver disease in elderly patients. ( 29432700 )
2018
16
Role of genetic and metabolism in non-alcoholic fatty liver disease. ( 29442484 )
2018
17
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. ( 29427497 )
2018
18
Future therapy for non-alcoholic fatty liver disease. ( 29427492 )
2018
19
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. ( 29415050 )
2018
20
Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. ( 29441049 )
2018
21
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. ( 28521870 )
2017
22
Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. ( 28933748 )
2017
23
Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. ( 28370150 )
2017
24
Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. ( 28936407 )
2017
25
Endocrine-disrupting chemicals and fatty liver disease. ( 28524171 )
2017
26
Roles of silent information regulator 1-serine/arginine-rich splicing factor 10-lipin 1 axis in the pathogenesis of alcohol fatty liver disease. ( 28467182 )
2017
27
Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. ( 28523578 )
2017
28
Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. ( 28075394 )
2017
29
Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. ( 28081779 )
2017
30
Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by (18)F-fluorodeoxyglucose positron emission tomography. ( 28081780 )
2017
31
Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. ( 28521774 )
2017
32
Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway. ( 28932253 )
2017
33
Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. ( 28937599 )
2017
34
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease. ( 28092906 )
2017
35
C-C chemokine receptor type 5 deficiency exacerbates alcoholic fatty liver disease through pro-inflammatory cytokines and chemokines-induced hepatic inflammation. ( 27859576 )
2017
36
The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. ( 28253210 )
2017
37
Identification of Potential Plasma Biomarkers for Nonalcoholic Fatty Liver Disease by Integrating Transcriptomics and Proteomics in Laying Hens. ( 28077733 )
2017
38
Author Reply-Bariatric Surgery and Liver Function Tests in Nonalcoholic Fatty Liver Disease. ( 28091895 )
2017
39
Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity - a randomized trial. ( 28941598 )
2017
40
Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. ( 27995687 )
2017
41
Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes. ( 29437160 )
2017
42
Histopathology, grading and staging of nonalcoholic fatty liver disease. ( 28948754 )
2017
43
Insulin-like growth factor 1 and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents. ( 27889912 )
2017
44
Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. ( 28473851 )
2017
45
Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis. ( 28912806 )
2017
46
Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma. ( 29348947 )
2017
47
Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. ( 28936403 )
2017
48
Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. ( 28326329 )
2017
49
Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population. ( 28637594 )
2017
50
Interferon lambda 4 rs368234815 TT>I'G variant is associated with liver damage in patients with nonalcoholic fatty liver disease. ( 28741298 )
2017

Variations for Fatty Liver Disease

Expression for Fatty Liver Disease

Search GEO for disease gene expression data for Fatty Liver Disease.

Pathways for Fatty Liver Disease

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.33 ADIPOQ ADIPOR2 CYP2E1 IL6 INS INSR
2
Show member pathways
12.81 ADIPOQ FABP1 LEP PPARA SREBF1 TNF
3
Show member pathways
12.68 ADIPOQ IL6 INS INSR LEP RETN
4 12.42 ADIPOQ FABP1 INS INSR SREBF1
5
Show member pathways
12.4 INS INSR MAPK8 MLXIPL SREBF1
6
Show member pathways
12.36 ADIPOQ ADIPOR2 INS INSR LEP LEPR
7
Show member pathways
12.27 ADIPOQ ADIPOR2 INS MLXIPL
8
Show member pathways
12.23 GGT1 IL6 INS INSR TNF
10
Show member pathways
12.18 KRT18 MAPK8 SREBF1 TNF
11
Show member pathways
12.05 ADIPOQ ADIPOR2 INS INSR
12
Show member pathways
11.99 IL6 INS INSR MAPK8
13
Show member pathways
11.81 ADIPOQ INS INSR MAPK8 TNF
14 11.79 ADIPOQ IL6 INS LEP
15 11.66 IL6 MAPK8 TNF
16 11.64 ADIPOQ ADIPOR2 LEP LEPR MAPK8 PPARA
17 11.63 ADIPOQ FABP1 PPARA
18
Show member pathways
11.6 IL6 INS INSR MAPK8 MLXIPL PPARA
19 11.59 INS INSR MAPK8
20 11.5 IL6 INS MAPK8
21 11.48 INS INSR LEP LEPR
22 11.46 IL6 MAPK8 TNF
23 11.4 ADIPOQ IL6 INS LEP PNPLA3 PPARA
24 10.98 ADIPOQ IL6 INSR LEP MAPK8 TNF

GO Terms for Fatty Liver Disease

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.97 ADIPOR2 LEP MTTP PNPLA3 PPARA SREBF1
2 regulation of receptor activity GO:0010469 9.95 ADIPOQ IL6 INS LEP RETN TNF
3 cholesterol metabolic process GO:0008203 9.86 LEP LEPR SREBF1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 ADIPOQ IL6 INS
5 cellular response to insulin stimulus GO:0032869 9.85 ADIPOQ INSR SREBF1
6 response to nutrient GO:0007584 9.84 ADIPOQ ADIPOR2 LEP
7 insulin receptor signaling pathway GO:0008286 9.84 INS INSR SREBF1
8 positive regulation of protein kinase B signaling GO:0051897 9.84 INS INSR LEP TNF
9 response to insulin GO:0032868 9.83 LEP PPARA RETN
10 regulation of insulin secretion GO:0050796 9.81 LEP SREBF1 TNF
11 response to glucocorticoid GO:0051384 9.8 ADIPOQ IL6 TNF
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 IL6 RETN TNF
13 negative regulation of fat cell differentiation GO:0045599 9.75 ADIPOQ IL6 TNF
14 positive regulation of MAPK cascade GO:0043410 9.73 IL6 INS INSR LEP
15 circadian rhythm GO:0007623 9.71 ADIPOQ LEP MTTP SREBF1
16 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.69 ADIPOQ PPARA
17 positive regulation of insulin receptor signaling pathway GO:0046628 9.69 INS LEP
18 fatty acid homeostasis GO:0055089 9.69 INS MLXIPL
19 positive regulation of nitric oxide biosynthetic process GO:0045429 9.69 INS INSR TNF
20 positive regulation of lipid biosynthetic process GO:0046889 9.68 INS MLXIPL
21 negative regulation of glucose import GO:0046325 9.67 LEP TNF
22 regulation of energy homeostasis GO:2000505 9.67 LEPR MLXIPL
23 sexual reproduction GO:0019953 9.66 LEP LEPR
24 positive regulation of fatty acid beta-oxidation GO:0032000 9.65 FABP1 PPARA
25 leptin-mediated signaling pathway GO:0033210 9.65 LEP LEPR
26 negative regulation of appetite GO:0032099 9.64 LEP PPARA
27 regulation of fatty acid biosynthetic process GO:0042304 9.64 ADIPOQ ADIPOR2
28 regulation of fatty acid metabolic process GO:0019217 9.62 PPARA SREBF1
29 glucose metabolic process GO:0006006 9.62 ADIPOQ INS LEP TNF
30 regulation of bone remodeling GO:0046850 9.61 LEP LEPR
31 negative regulation of feeding behavior GO:2000252 9.61 INS RETN
32 adiponectin-activated signaling pathway GO:0033211 9.6 ADIPOQ ADIPOR2
33 positive regulation of respiratory burst GO:0060267 9.59 INS INSR
34 neuron projection maintenance GO:1990535 9.58 INS INSR
35 positive regulation of STAT protein import into nucleus GO:2000366 9.57 IL6 LEP
36 positive regulation of developmental growth GO:0048639 9.56 INSR LEP
37 positive regulation of protein complex disassembly GO:0043243 9.55 INSR TNF
38 positive regulation of glycolytic process GO:0045821 9.54 INS INSR MLXIPL
39 bone growth GO:0098868 9.46 LEP LEPR
40 negative regulation of gluconeogenesis GO:0045721 9.43 ADIPOQ INS LEPR
41 negative regulation of lipid storage GO:0010888 9.33 IL6 LEP TNF
42 positive regulation of glucose import GO:0046326 9.26 ADIPOQ ADIPOR2 INS INSR
43 glucose homeostasis GO:0042593 9.17 ADIPOQ ADIPOR2 INS INSR LEP LEPR
44 negative regulation of apoptotic process GO:0043066 10.1 FABP1 IL6 KRT18 LEP MAPK8
45 positive regulation of cell proliferation GO:0008284 10.09 IL6 INS INSR LEP MLXIPL
46 positive regulation of transcription, DNA-templated GO:0045893 10 IL6 INSR MLXIPL PPARA SREBF1 TNF

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 ADIPOQ INS LEP RETN

Sources for Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....